Dudediligence.

CRISPR Therapeutics AG

CRSPNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$602,000Sep ’24$35.7MDec ’24$865,000Mar ’25$892,000Jun ’25$889,000Sep ’25$864,000Dec ’25$1.5MMar ’26$10.2MJun ’26
Net income, by quarter
−$85.9MSep ’24−$37.3MDec ’24−$136.0MMar ’25−$208.5MJun ’25−$106.4MSep ’25−$130.6MDec ’25−$122.9MMar ’26−$91.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$915.0M$1.2M$371.2M$37.3M$3.5M
Operating income$373.5M−$673.2M−$222.5M−$466.6M−$664.6M
Net income$377.7M−$650.2M−$153.6M−$366.3M−$581.6M
Operating cash flow$539.0M−$495.7M−$260.4M−$142.8M−$345.0M
Free cash flow$457.3M−$532.9M−$269.8M−$144.7M−$345.9M
Cash$923.0M$211.9M$389.5M$298.3M$347.6M
Debtnone on filenone on filenone on filenone on file$0.00
Shares outstanding77.0M78.5M80.0M85.7M95.9M